Bullish
Eli Lilly's Jaypirca (pirtobrutinib) approved as first-line treatment for CLL/SLL
Eli Lilly's Jaypirca (pirtobrutinib) has received FDA approval as a first-line treatment for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not been previously treated and do not have a known 17p deletion. This approval is expected to expand the drug's market potential and strengthen Lilly's oncology portfolio.
Key points
- FDA approval of Jaypirca as first-line treatment for CLL/SLL
- No significant market-moving news in the past 24 hours
Sources
- Eli Lilly (LLY) Gains FDA Approval for Jaypirca as First-Line Treatment in CLL/SLLGuruFocus News · October 2, 2026
- Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLLPR Newswire · October 2, 2026
AI-generated from public news sources. Not financial advice.
